[1] Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop longterm treatment with adefovir. Gastroenterology,2012,143:629-636.e1.
[2] Jeng WJ, Chen YC, Chien RN, et al. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of NAsleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology,2018,68:425-434.
[3] Chen CH, Hung CH, Wang JH, et al. The incidence of hepatitis B surface antigen loss between hepatitis B e antigen-negative noncirrhotic patients who discontinued or continued entecavir therapy. J Infect Dis,2019,219:1624-1633.
[4] Liaw YF. Finite NAsleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. Hepatol Int,2019,13:665-673.
[5] Chang ML, Liaw YF. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J Hepatol,2014,61:1407-1417.
[6] Jeng WJ, Chen YC, Sheen IS, et al. Clinical relapse after cessation of tenofovir therapy in HBeAgnegative patients. Clin Gastroenterol Hepatol,2016,14:1813-1820.
[7] Berg T, Simon KG, Mauss S, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients-FINITE study. J Hepatol,2017,67:918-924.
[8] H?ner zu Siederdissen C, Rinker F, Maasoumy B, et al. Viral and host responses after stopping long-term NAsleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Infect Dis, 2016,214:1492-1497.
[9] Liaw YF. Hepatitis B Flare After Cessation of NAsleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B: To Retreat or Not to Retreat. J Hepatol, 2021,73(2):843-852.
[10] Liaw YF, Yang SS, Chen TJ, et al. Acute exacerbation in hepatitis B e antigen-positive chronic type B hepatitis: a clinicopathological study. J Hepatol,1985,1:227-233.
[11] Liaw YF, Tai DI, Chu CM, et al. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody positive patients. Hepatology,1987,7:20-23.
[12] Ghany MG, Feld JJ, Chang KM, et al. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. Lancet Gastroenterol Hepatol,2020,5:406-417.
[13] Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat Rev Gastroenterol Hepatol,2019,16:662-675.
[14] Wang H, Luo H, Wan X, et al. TNF-α/IFN-γprofile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection. J Hepatol,2020,72:45-56.
[15] Lim SG, Wai CT, Rajnakova A, et al. Fatal hepatitis B reactivation following discontinuation of NAsleoside analogues for chronic hepatitis B. Gut,2002,51:597-599.
[16] Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int,2012,6:531-561.
[17] Brahmania M, Lombardero M, Hansen BE, et al. Association between severe serum alanine aminotransferase flares and hepatitis B e antigen seroconversion and HBV DNA decrease in untreated patients with chronic HBV infection. Clin Gastroenterol Hepatol,2019,17:2541-2551.
[18] Papatheodoridis GV, Manolakopoulos S, Su TH, et al. Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B. Hepatology,2018,68:415-424.
[19] Liem KS, Fung S, Wong DK, et al. Limited sustained after stopping NAsleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial. Gut, 2019,68:2206-2213.
[20] 刘志红,零小樟,江建宁. 慢性乙型肝炎抗病毒治疗终点标志物研究进展. 中国实用内科杂志,2020,40:451-456.
[21] Chien RN, Liaw YF. Re-treatment for severe hepatitis flare in HBeAg-negative chronic hepatitis B: an appraisal with combined HBsAg/ALT kinetics. J Viral Hepat,2020,27:544-547.
[22] Jeng WJ, Chang ML, Liaw YF. Off-therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg-negative patients. J Viral Hepat,2019,26:1019-1026. |
